D. Berger

发表

Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects

N. Chirmule, V. Jawa, S. Swanson, 2010, Annals of Hematology.

Successful treatment of cyclic thrombocytopenia with thrombopoietin‐mimetic agents: A report of two patients

J. George, L. Rice, P. Bose, 2009, American journal of hematology.

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

Yow-Ming C Wang, H. Kantarjian, P. Fenaux, 2011, Cancer.

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.

J. Gabrilove, P. Greenberg, H. Kantarjian, 2010, Blood.

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

R. Larson, H. Kantarjian, P. Fenaux, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase II Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Patients with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

R. Larson, J. Franklin, L. Dreisbach, 2009 .

Romiplostim or standard of care in patients with immune thrombocytopenia.

B. Chong, F. Rodeghiero, I. Pabinger, 2010, The New England journal of medicine.

Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.

D. Brizel, W. Mendenhall, B. Murphy, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS).

H. Kantarjian, P. Fenaux, M. Sekeres, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.

Q. Le, Yuhchyau Chen, Harold Kim, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial.

L. Cerezo, J. Giralt, M. Henke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531)

E. Katodritou, E. Terpos, K. Zervas, 2009, American journal of hematology.

Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h

T. Gerds, R. Wäsch, S. Mielke, 2003, Anti-cancer drugs.

A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura

T. Nagasawa, K. Ando, S. Hashino, 2009, International journal of hematology.

A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).

J. Bussel, V. Blanchette, G. Buchanan, 2009 .

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

J. Bussel, A. Newland, J. Wasser, 2009 .

Home Administration of Romiplostim by Patients with Chronic Immune Thrombocytopenia (ITP).

R. Lyons, R. Mandanas, R. Boccia, 2009 .

Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study.

V. Diehl, N. Schmitz, H. Döhner, 2006, Haematologica.

Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small Cell Lung Cancer

Bartomeu Massuti, M. Krzakowski, Yuhchyau Chen, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

J. Bussel, T. Guthrie, A. Newland, 2008 .

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

B. Chong, F. Rodeghiero, I. Pabinger, 2009 .

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP)

J. Bussel, A. Newland, J. Wasser, 2009 .

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label

J. Bussel, T. Guthrie, A. Newland, 2008 .

Successful treatment of cyclic thrombocytopenia with thrombopoietin‐mimetic agents: A report of two patients

J. George, F. Magrini, A. Cortelezzi, 2009, American journal of hematology.

EVALUATING THE LONG-TERM EFFICACY OF ROMIPLOSTIM (AMG 531) IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) DURING AN OPEN-LABEL EXTENSION STUDY

E. Vellenga, M. Sanz, P. Boekhorst, 2008 .